Meanwhile, it has been shown that CXCL12+ iCAFs are increased during colorectal cancer progression, and the pathway related to drug metabolism is activated in these cells [216], suggesting that CXCL12+ iCAFs are associated with chemotherapy resistance in patients with colorectal cancer. This evidence concerns the gene CXCL12 and colorectal cancer.